To evaluate the therapeutic potential of ASH1L inhibition in HCC, we utilized a CCL2‐neutralizing antibody (CCL2 Ab) and the CSF1R inhibitor BLZ945 to block CCL2 and CSF1 signaling in a DEN/CCl4‐induced mouse model. Here, CSF1 is linked to hepatocellular carcinoma.